Eosinophilic Esophagitis
Conditions
Keywords
Eosinophilic Esophagitis; PPIs, children, elimination diet, topical steroids
Brief summary
1. Registry of demographic, clinical, endoscopic and histological data at baseline. 2. Registry of patients treated with PPI: * Clinical, endoscopic and histological response at 8-12 weeks of induction treatment * Clinical, endoscopic and histological response at 6 and 12 months weeks of maintenance treatment 3. Registry of patients treated with two foods elimination diet: * Clinical, endoscopic and histological response at 8-12 weeks of induction treatment * Identification of food trigger: milk, gluten or milk and gluten * Clinical, endoscopic and histological response at one year elimination of food trigger * Registry of adverse events 4. Registry of patients treated with swallowed steroids (budesonide or fluticasone): * Clinical, endoscopic and histological response at 8-12 weeks of induction treatment * Clinical, endoscopic and histological response at 6 months of maintenance steroid treatment * Registry of adverse events
Interventions
OTHERno intervention
no intervention
Sponsors
Sociedad Espanola de Gastroenterologia, Hepatologia y Nutricion Pediatrica
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Months to 18 Years
Inclusion criteria
* Children from 1 month to 18 years with a new diagnosis of eosinophilic esophagitis (EoE) according to the recent European guidelines (symptoms of esophageal dysfunction + eosinophilic infiltrate of the esophagus \> 15 eos / CGA) * And that they need to start treatment with any of the following options: PPI, diet excluding cow's milk and gluten, or swallowed corticosteroids .
Exclusion criteria
* Presence of pathological eosinophilia at the gastric or duodenal level (eosinophilic gastroenteritis) * Simultaneous treatment with more than one treatment modality (PPI, empirical elimination diet, swallowed corticosteroids).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete histological remission | 12 weeks | Complete histological remission response defined as ≤5 eosinophils/hpf in all biopsies performed |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Partial histological remission | 12 weeks | Partial histological remission response defined as 5-15 eosinophils /hpf in all biopsies |
| Clinical remission | 12 weeks | Clinical remission (specific questionnaire) |
Countries
Spain
Contacts
Primary ContactCarolina Gutierrez-Junquera, MD, PHD
Backup ContactBelén Ruiz-Antorán, MD, PHD
Outcome results
None listed